Category Archives: Biotechnology

NEW YORK, NY--(Marketwire -07/25/12)- The Biotechnology Industry has been soaring in 2012 as companies -- both large and small -- have shown impressive growth. The SPDR S&P Biotech ETF (XBI) and the First Trust NYSE Arca Biotech Index ETF (FBT) year-to-date are up 38 percent and 37 percent, respectively, outperforming the broader market by a wide margin. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Aastrom Biosciences, Inc. (ASTM) and Geron Corporation (GERN).

Access to the full company reports can be found at: http://www.ParagonReport.com/ASTM http://www.ParagonReport.com/GERN

Despite having to negotiate a more challenging regulation process, biotech companies have continued to show investors strong gains in 2012. The FDA Amendments Act of 2007 forced regulators to increase standards for approvals of new drugs, introducing mandatory risk evaluation and mitigation strategies. According to a Pharmaceuticals & Biotechnology report from IMAP, several pharmaceutical firms have altered their drug portfolios from primary care driven blockbusters towards specialties such as oncology, immunology and inflammation, where the medical need is "so high that prices are more easily accepted by the regulators."

Paragon Report releases regular market updates on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.ParagonReport.com and get exclusive access to our numerous stock reports and industry newsletters.

Aastrom Biosciences is dedicated to the development of stem cell treatments for critical cardiovascular diseases. Aastrom is currently evaluating its autologous cellular therapies in late-stage U.S. clinical trials in the treatment of critical limb ischemia (CLI) and dilated cardiomyopathy (DCM). These critical diseases are associated with significant morbidity and mortality and very limited treatment options.

Geron is a biopharmaceutical company developing first-in-class therapies for cancer. The company has two lead product candidates in clinical development, imetelstat and GRN1005. Imetelstat is a telomerase inhibitor that is being evaluated in four Phase 2 clinical trials. GRN1005 is a peptide-drug conjugate that is designed to transport a proven anti-cancer drug, paclitaxel.

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: http://www.paragonreport.com/disclaimer

See the original post:
Despite Facing More Challenging Regulation Process Biotech Companies Showing Impressive Growth in 2012

NOKOMIS, Fla.--(BUSINESS WIRE)--

Rainbow BioSciences, the biotechnology subsidiary of Rainbow Coral Corp. (RBCCD), announced today that the company has signed an extension of its letter of intent with emerging biotech innovator Amarantus BioSciences (AMBS).

Amarantus is on the verge of delivering startling new breakthroughs in the diagnosis and treatment of neurological disorders from Parkinsons disease to Traumatic Brain Injury (TBI). Amarantus owns the rights to a promising therapeutic protein known as MANF that prevents a type of cell death called apoptosis as well as the license to a groundbreaking diagnostic platform called NuroPro that allows neurologists to accurately diagnose and track the progression of Parkinsons disease in patients.

Amarantus is doing exciting work that we believe will change the way neurological diseases are diagnosed and treated, said RBCC CEO Patrick Brown. They have several current projects that were interested in, and an extension of the terms of our previous LOI will allow us to complete our due diligence toward choosing a direction with this life-saving company with the most potential return for our shareholders.

Once RBCC completes its due diligence, the companies will negotiate a possible deal for RBCC to provide funding and expertise toward the development and marketing of one or more of Amarantus projects.

Rainbow BioSciences is working to develop new medical and research technology innovations to compete alongside companies such as Cell Therapeutics, Inc. (NASDAQ:CTIC),Biogen Idec Inc. (NASDAQ:BIIB) and Elan Corp. (NYSE:ELN).

For more information on Rainbow BioSciences, RBCCs biotechnology division, please visit http://www.rainbowbiosciences.com/investors.html.

About Rainbow BioSciences

Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB:RBCC). The company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit our website at [www.RainbowBioSciences.com]. For investment information and performance data on the company, please visit http://www.RainbowBioSciences.com/investors.html.

Notice Regarding Forward-Looking Statements

More:
RBCC Extends Joint Venture Negotiations With Amarantus

NEW YORK, NY--(Marketwire -07/24/12)- The Biotechnology Industry has been soaring in 2012 as companies -- both large and small -- have shown impressive growth. The SPDR S&P Biotech ETF (XBI) and the First Trust NYSE Arca Biotech Index ETF (FBT) year-to-date are up 38 percent and 37 percent, respectively, outperforming the broader market by a wide margin. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on AEterna Zentaris Inc. (AEZS) (AEZ.TO) and MannKind Corporation (MNKD).

Access to the full company reports can be found at:

http://www.ParagonReport.com/AEZS http://www.ParagonReport.com/MNKD

Despite having to negotiate a more challenging regulation process biotech companies have continued to show investors strong gains in 2012. The FDA Amendments Act of 2007 forced regulators to increase standards for approvals of new drugs, introducing mandatory risk evaluation and mitigation strategies. According to a Pharmaceuticals & Biotechnology report from IMAP, several pharmaceutical firms have altered their drug portfolios from primary care driven blockbusters towards specialties such as oncology, immunology and inflammation, where the medical need is "so high that prices are more easily accepted by the regulators."

Paragon Report releases regular market updates on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.ParagonReport.com and get exclusive access to our numerous stock reports and industry newsletters.

Aeterna Zentaris is an oncology and endocrinology drug development company currently investigating treatments for various unmet medical needs. The Company's pipeline encompasses compounds at all stages of development, from drug discovery through to marketed products. The company last month reported its Japanese partner Yakult Honsha has initiated a Phase 1 trial in multiple myeloma, a form of blood cancer, with perifosine.

MannKind is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Their lead investigational product candidate, AFREZZA is a novel, ultra rapid-acting mealtime insulin therapy. AFREZZA is in late stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes.

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: http://www.paragonreport.com/disclaimer

Link:
Despite Navigating More Challenging Regulation Process Biotech Companies Thriving in 2012

SEATTLE, July 24, 2012 (GLOBE NEWSWIRE) -- Plandai Biotechnology, Inc. (PLPL) a producer of highly bioavailable plant extracts, today announced that it has received the funds from the initial draw down on the 100 million Rand (US $13 million) loan from the Land and Agriculture Bank of South Africa. The total amount of the first draw was 49 million Rand (approx. $5.6 million USD).

Plandai Chairman and Chief Executive Officer, Roger Duffield, commented, "This initial draw is the first step in moving towards full-scale production of our highly bioavailable botanical extracts. These funds will allow us to complete the engineering of the plant and equipment and acquire the necessary components so that we can be operational in the 2013- 2014 tea season. Further drawdowns will provide the necessary investment to rejuvenate and operate the Senteeko Tea Estate as a modern and efficient farming enterprise that will produce high levels of polyphenolic catechin in quality green tea leaf l." Mr. Duffield continued; "Our daily expected processing output from the processing of live green tea leaf should yield between 400 -600 kg of extract; and during the dormant tea growing period, the extraction facility has the flexibility to be utilized to recover valuable bioflavonoids and limonoids from citrus fruits, giving the processing facility the ability to operate all year round."

Several epidemiological studies have shown beneficial effects of green tea in cancer, cardiovascular, and neurological diseases. The health benefits associated with green tea consumption have also been corroborated in animal studies of cancer chemoprevention, hypercholesterolemia, atherosclerosis, Parkinson's disease, Alzheimer's disease, and other aging-related disorders. However, the use of current green tea and green tea extracts as a cancer preventive or for other health benefits has been confounded by the low oral bioavailability of its active polyphenolic catechins, particularly epigallocatechin-3-gallate (EGCG).

The proprietary CRS hydrodynamic system developed by Plandai releases antioxidants that are recovered in the process in a form more readily absorbable in human tissue.

The Land and Agriculture Bank of South Africa (http://www.landbank.co.za/) is a specialist agricultural bank guided by a government mandate to provide financial services to the commercial farming sector and to agri-business and to facilitate access to finance by new entrants to agriculture from historically disadvantaged backgrounds.

About Plandai Biotechnology, Inc.

Plandai Biotechnology, Inc. focuses on the farming of whole fruits, vegetables and live plant material and the production of proprietary functional foods and botanical extracts for the health and wellness industry. Its principle holdings consist of land, farms and infrastructure in South Africa. Web site: http://www.plandaibiotech.com/

Safe Harbor Statement

The information provided may contain forward-looking statements and involve risks and uncertainties. Results, events and performances could vary from those contemplated. These statements involve risks and uncertainties which may cause actual results, expressed or implied, to differ from predicted outcomes. Risks and uncertainties include product demand, market competition, and Plandai's ability to meet current or future plans. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Plandai is not obliged to publicly release revisions to any forward-looking statement, to reflect events or circumstances afterward, or to disclose unanticipated occurrences, except as required under applicable laws.

Link:
Plandai Biotechnology, Inc. Receives $5.6 Million Initial Funding From the Land and Agriculture Bank of South Africa

NEW YORK, NY--(Marketwire -07/24/12)- The Biotechnology Industry has been soaring in 2012 as companies -- both large and small -- have shown impressive growth. The SPDR S&P Biotech ETF (XBI) and the First Trust NYSE Arca Biotech Index ETF (FBT) year-to-date are up 38 percent and 37 percent, respectively, outperforming the broader market by a wide margin. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on StemCells, Inc. (STEM) and Keryx Biopharmaceuticals (KERX).

Access to the full company reports can be found at:

http://www.ParagonReport.com/STEM http://www.ParagonReport.com/KERX

Despite having to negotiate a more challenging regulation process biotech companies have continued to show investors strong gains in 2012. The FDA Amendments Act of 2007 forced regulators to increase standards for approvals of new drugs, introducing mandatory risk evaluation and mitigation strategies. According to a Pharmaceuticals & Biotechnology report from IMAP, several pharmaceutical firms have altered their drug portfolios from primary care driven blockbusters towards specialties such as oncology, immunology and inflammation, where the medical need is "so high that prices are more easily accepted by the regulators."

Paragon Report releases regular market updates on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.ParagonReport.com and get exclusive access to our numerous stock reports and industry newsletters.

StemCells is engaged in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery. The company recently announced preclinical data demonstrating that its proprietary human neural stem cells restored memory and enhanced synaptic function in two animal models relevant to Alzheimer's disease. Shares of the company have soared nearly 90 percent this year.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease. Keryx is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Shares of the company have rebounded nearly 50 percent over the last three months.

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: http://www.paragonreport.com/disclaimer

Continue reading here:
StemCells and Keryx Biopharmaceuticals Showing Strong Gains as Biotechnology Industry Soars in 2012

Posted on July 23, 2012, Monday

PLATFORM FOR OPPORTUNITIES: The meeting provided opportunities for both parties to explore collaboration opportunities available in Malaysia and their home countries.

KUALA LUMPUR: The Malaysian Biotechnology Corporation (BiotechCorp) recently held a networking lunch with foreign diplomatic corps to provide them with the latest highlights pertaining to the biotechnology industry.

The event was attended by foreign ambassadors, diplomats, as well as members of the foreign trade from the United States, Canada, Italy, Netherlands, Saudi Arabia, Venezuela, Azerbaijan, South Africa, Uruguay, Swaziland, China, and the Philippines.

In a statement, BiotechCorp said the meeting provided opportunities for both parties to explore collaboration opportunities available in Malaysia and their home countries.

BiotechCorp chief executive officer Datuk Dr Mohd Nazlee Kamal was quoted as saying in the statement that the event served as an ideal platform for the corporation to promote foreign direct investments in biotechnology.

It also helped create market access for local biotech products and services, particularly for BioNexus status companies and strengthen networking between BiotechCorp and Diplomatic Corps, he added. Bernama

<< Previous Entry - Next Entry >>

Visit link:
Biotechcorp updates diplomatic corp on industry developments